WO2005009408B1 - Sustained release dosage forms of anesthetics for pain management - Google Patents
Sustained release dosage forms of anesthetics for pain managementInfo
- Publication number
- WO2005009408B1 WO2005009408B1 PCT/US2003/034763 US0334763W WO2005009408B1 WO 2005009408 B1 WO2005009408 B1 WO 2005009408B1 US 0334763 W US0334763 W US 0334763W WO 2005009408 B1 WO2005009408 B1 WO 2005009408B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- sustained release
- polymer
- anesthetic
- release dosage
- Prior art date
Links
- 230000003444 anaesthetic Effects 0.000 title claims abstract 26
- 239000002552 dosage form Substances 0.000 title claims 42
- 230000002459 sustained Effects 0.000 title claims 33
- 239000003193 general anesthetic agent Substances 0.000 title claims 2
- 229940035674 ANESTHETICS Drugs 0.000 title 1
- 229920000642 polymer Polymers 0.000 claims abstract 28
- 239000002904 solvent Substances 0.000 claims abstract 21
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960003150 bupivacaine Drugs 0.000 claims abstract 7
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 12
- -1 levo-ropivacaine Chemical compound 0.000 claims 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 11
- 239000004310 lactic acid Substances 0.000 claims 11
- 235000014655 lactic acid Nutrition 0.000 claims 11
- 229920001577 copolymer Polymers 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N Caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- 229960002622 Triacetin Drugs 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 239000001087 glyceryl triacetate Substances 0.000 claims 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 2
- 239000002357 osmotic agent Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 claims 1
- URZHQOCYXDNFGN-UHFFFAOYSA-N 2,4,6-trimethyl-2,4,6-tris(3,3,3-trifluoropropyl)-1,3,5,2,4,6-trioxatrisilinane Chemical compound FC(F)(F)CC[Si]1(C)O[Si](C)(CCC(F)(F)F)O[Si](C)(CCC(F)(F)F)O1 URZHQOCYXDNFGN-UHFFFAOYSA-N 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N Diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 1
- YSAVZVORKRDODB-WDSKDSINSA-N Diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 claims 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N Ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 1
- LZCLXQDLBQLTDK-UHFFFAOYSA-N Ethyl lactate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims 1
- 229960003976 Etidocaine Drugs 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- 239000004348 Glyceryl diacetate Substances 0.000 claims 1
- UYXTWWCETRIEDR-UHFFFAOYSA-N Glyceryl tributyrate Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 1
- LEBVLXFERQHONN-INIZCTEOSA-N Levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920001083 Polybutene Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- 229960001549 Ropivacaine Drugs 0.000 claims 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N Ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 1
- 229960002372 Tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N Triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960002903 benzyl benzoate Drugs 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 229940116333 ethyl lactate Drugs 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- 229940074076 glycerol formal Drugs 0.000 claims 1
- 235000019443 glyceryl diacetate Nutrition 0.000 claims 1
- 239000012456 homogeneous solution Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229960004288 levobupivacaine Drugs 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 229920002866 paraformaldehyde Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 229920001707 polybutylene terephthalate Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920001855 polyketal Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 229920001897 terpolymer Polymers 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- QZCLKYGREBVARF-UHFFFAOYSA-N tributyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims 1
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N tributyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N γ-lactone 4-hydroxy-butyric acid Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drugs Drugs 0.000 abstract 2
- 238000010276 construction Methods 0.000 abstract 1
Abstract
Drug delivery systems and kits are provided that release an anesthetic, such as bupivacaine, over a short duration. Methods of administering and preparing such systems are also provided. Drug delivery systems include a short duration gel vehicle and an anesthetic dissolved or dispersed in the gel vehicle. The gel vehicle comprises a low molecular weight bioerodible, biocompatible polymer and a water-immiscible solvent in an amount effective to plasticize the polymer and form a gel with the polymer. In some instances, a component solvent is used along with the water-immiscible solvent. An efficacy ratio, which is one way to measure the efficacy of a delivery system, can be controlled based on, for example, the construction of the gel vehicle to achieve a desired release profile.
Claims
1. A sustained release dosage form of an anesthetic comprising: a short duration gel vehicle comprising a low molecular weight bioerodible, biocompatible polymer and a water-immiscible solvent in an amount effective to plasticize the polymer and form a gel therewith; an anesthetic dissolved or dispersed in the gel vehicle.
2. The sustained release dosage form of claim 1 further comprising a controllable efficacy ratio to achieve a release profile.
3. The sustained release dosage form of claim 2 wherein the efficacy ratio is between about 1 and 200, preferably between about 5 and 100.
4. The sustained release dosage form of any preceding claim wherein the sustained release occurs in a period of less than or equal to about fourteen days, preferably wherein the sustained release occurs in a period of less than or equal to about seven days, and more preferably wherein the sustained release lasts for a period of between about 24 hours and about seven days.
5. The sustained release dosage form of any preceding claim wherein the anesthetic is selected from the group consisting of: bupivacaine, levo-bupivacaine, ropivacaine, levo-ropivacaine, tetracaine, etidocaine, levo-etidocaine, dextro-etidocaine, levo-etidocaine, dextro-etidocaine, levo- mepivacaine, and combinations thereof.
6. The sustained release dosage form of any preceding claim wherein the anesthetic comprises bupivacaine.
7. The sustained release dosage form of any preceding claim wherein the solvent has a miscibility in water of less than or equal to about 7 weight % at25 C.
8. The sustained release dosage form of any preceding claim wherein the dosage form is free of solvents having a miscibility in water that is greater than 7 weight % at25 C.
9. The sustained release dosage form of any preceding claim wherein the solvent is selected from the group consisting of: an aromatic alcohol, lower alkyl esters of aryl acids, lower aralkyl esters of aryl acids, aryl ketones, aralkyl ketones, lower alkyl ketones, lower alkyl esters of citric acid, and combinations thereof.
10. The sustained release dosage form of any preceding claim wherein the solvent comprises a member selected from the group consisting of benzyl alcohol, benzyl benzoate, ethyl benzoate, triacetin and mixtures thereof.
11. The sustained release dosage form of any preceding claim wherein the solvent comprises a component solvent selected from the group consisting of: triacetin, diacetin, tributyrin, triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethylglycerides, triethyl phosphate, diethyl phthalate, diethyl tartrate, mineral oil, polybutene, silicone fluid, glylcerin, ethylene glycol, polyethylene glycol, octanol, ethyl lactate, propylene glycol, propylene carbonate, ethylene carbonate, butyrolactone, ethylene oxide, propylene oxide, N-methyl-2-pyrrolidone, 2- pyrrolidone, glycerol formal, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, and l-dodecylazacyclo-heptan-Z-one, and combinations thereof.
12. The sustained release dosage form of any preceding claim wherein the polymer comprises a lactic acid-based polymer or a copolymer of lactic acid and glycolic acid (PLGA) or a caprolactone-based polymer or is selected from the group consisting of : polylactides, polyglycolides, poly (caprolactone) , polyanhydrides, polyamines, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyphosphoesters, polyesters, polybutylene terephthalate, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid) , poly (amino acids) , polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, polysaccharides, chitin, chitosan, hyaluronic acid, and copolymers, terpolymers and mixtures thereof.
13. The sustained release dosage form of claim 12 wherein the polymer comprises a copolymer of lactic acid and glycolic acid (PLGA) and wherein the copolymer has a monomer ratio of lactic acid to glycolic acid of approximately 50: 50.
14. The sustained release dosage form of claim 12 or 13 wherein the polymer comprises an ester end group or a carboxylic acid end group.
15. The sustained release dosage form of any preceding claim wherein the polymer has a weight average molecular weight of between about 3,000 and about 10,000, preferably wherein the polymer has a weight average molecular weight of between about 3,000 and about 8,000, more preferably wherein the polymer has a weight average molecular weight of between about 4,000 and about 6,000, and more preferably wherein the polymer has a weight average molecular weight of about 5,000.
16. The sustained release dosage form of any preceding claim wherein the dosage form comprises from about 0.1 % to about 50 % anesthetic by weight, preferably wherein the dosage form comprises from about 0.5 % to about 40 % anesthetic by
5 weight, and more preferably wherein the dosage form comprises from about 1 % to about 30 % anesthetic by weight.
17. The sustained release dosage form of any preceding claim wherein the ratio between the polymer and the solvent is
10 between about 5: 95 and about 90: 10, preferably wherein the ratio between the polymer and the solvent is between about 20: 80 and about 80: 20, and more preferably wherein the ratio between the polymer and the solvent is between about 30: 70 and about 75: 25.
15
18. The sustained release dosage form of any preceding claim further comprising at least one of the following: an excipient, an emulsifying agent, a pore former, a solubility modulator for the anesthetic, and an osmotic agent.
20
19. The sustained release dosage form of any preceding claim wherein the anesthetic comprises particles having an average particle size of less than about 250 μm, preferably wherein the anesthetic comprises particles having an average particle
25 size of between about 5 μm and 250 μm, more preferably wherein the average particle size is between about 20 μm and about 125 μm, and more preferably wherein the average particle size is between about 38 μm and about 63 μm.
30 20. The sustained release dosage form of any preceding claim wherein the polymer comprises a lactic acid-based polymer and the anesthetic comprises bupivacaine, the dosage form further comprising a controllable efficacy ratio to achieve a release profile; and wherein the weight average molecular weight of
35 the lactic acid-based polymer is between about 3,000 and about 10 , 000 .
21. The sustained release dosage form of claim 20 wherein the polymer comprises a copolymer of lactic acid and glycolic
5 acid (PLGA) .
22. The sustained release dosage form of claim 21 wherein the copolymer has a monomer ratio of lactic acid to glycolic acid of approximately 50: 50.
10
23. The sustained release dosage form of claim 21 or 22 wherein the copolymer comprises poly (D, L-lactide-co-glycolide) .
15 24. The sustained release dosage form of claim 21 or 22 wherein the copolymer comprises poly (L- lactide-co-glycolide) .
25. Use of an anesthetic in the manufacture of a sustained 20 release dosage form as defined in any preceding claim for the treatment of local pain of a subject.
26. The use of claim 25 wherein the dosage form is for administering once.
25
27. The use of claim 25 wherein the dosage form is for topical application to the local pain, or wherein the dosage form is for injection at a location near the local pain, or wherein the dosage form is for delivering the anesthetic
30 systemically, or wherein the dosage form is for delivering the anesthetic to multiple sites.
28. The use of claim 27 wherein the dosage form is for injection at multiple locations surrounding the local pain.
35
29. The use of claim 25 wherein the dosage form is for repeated administration.
30. Use of bupivacaine in the manufacture of a sustained 5 release dosage form comprising a short duration gel vehicle, which comprises a low molecular weight bioerodible, biocompatible lactic acid-based polymer, and a water-immiscible solvent in an amount effective to plasticize the polymer and form a gel therewith; an anesthetic 10 comprising bupivacaine dissolved or dispersed in the gel vehicle ; and a controllable efficacy ratio to achieve a release profile, wherein the dosage form is for the treatment of post-surgical local pain of a subject.
15 31. The use of claim 30 wherein the polymer comprises a copolymer of lactic acid and glycolic acid (PLGA) .
32. The use of claim 31 wherein the copolymer has a monomer ratio of lactic acid to glycolic acid of approximately 50:
20 50.
33. A method of preparing a sustained release dosage form as defined in any one of claims 1 to 24, the method comprising: preparing a short duration gel vehicle comprising a
25 low molecular weight bioerodible, biocompatible polymer and a water-immiscible solvent in an amount effective to plasticize the polymer and form a gel therewith to create a polymer/solvent solution or gel; equilibrating the polymer/solvent mixture until a 30 clear homogeneous solution or gel is achieved; dissolving or dispersing an anesthetic into thepolymer/solvent solution or gel; blending the anesthetic and the polymer/solvent solution or gel to form a sustained release dosage form; and
35 controlling an efficacy ratio to achieve a release profile .
34. The method of claim 33 wherein the polymer/solvent solution or gel is equilibrated at a temperature between room
5 temperature and approximately 65°C.
35. The method of claim 33 or 34 wherein the anesthetic comprises bupivacaine.
10 36. A kit for administration of a sustained delivery of an anesthetic to local pain of a subject comprising: a short duration gel vehicle comprising a low molecular weight bioerodible, biocompatible polymer and a water-immiscible solvent, in an amount effective to 15 plasticize the polymer and form a gel therewith; an anesthetic dissolved or dispersed in the gel vehicle; and optionally, one or more of the following: an excipient; an emulsifying agent; 20 a pore former; a solubility modulator for the anesthetic, optionally associated with the anesthetic; and an osmotic agent; wherein at the least anesthetic agent, optionally 25 associated with the solubility modulator, is maintained separated from the solvent until the time of administration of the anesthetic to the subject.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05014193A MXPA05014193A (en) | 2003-06-25 | 2003-10-31 | Sustained release dosage forms of anesthetics for pain management. |
EP03778041A EP1638519A2 (en) | 2003-06-25 | 2003-10-31 | Sustained release dosage forms of anesthetics for pain management |
JP2005504650A JP2007521225A (en) | 2003-06-25 | 2003-10-31 | Sustained-release dosage form of anesthetic to manage pain |
BRPI0318373-4A BR0318373A (en) | 2003-06-25 | 2003-10-31 | sustained release dosage forms of pain control anesthetics |
CA002530357A CA2530357A1 (en) | 2003-06-25 | 2003-10-31 | Sustained release dosage forms of anesthetics for pain management |
AU2003286826A AU2003286826A1 (en) | 2003-06-25 | 2003-10-31 | Sustained release dosage forms of anesthetics for pain management |
IL172781A IL172781A0 (en) | 2003-06-25 | 2005-12-22 | Sustained release dosage forms of anesthetics for pain management |
NO20060295A NO20060295L (en) | 2003-06-25 | 2006-01-20 | Dosage forms with sustained release of pain management anesthetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/606,969 | 2003-06-25 | ||
US10/606,969 US20040001889A1 (en) | 2002-06-25 | 2003-06-25 | Short duration depot formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005009408A2 WO2005009408A2 (en) | 2005-02-03 |
WO2005009408A3 WO2005009408A3 (en) | 2006-01-19 |
WO2005009408B1 true WO2005009408B1 (en) | 2006-04-06 |
Family
ID=34103124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/034763 WO2005009408A2 (en) | 2003-06-25 | 2003-10-31 | Sustained release dosage forms of anesthetics for pain management |
Country Status (17)
Country | Link |
---|---|
US (7) | US20040001889A1 (en) |
EP (2) | EP1638519A2 (en) |
JP (1) | JP2007521225A (en) |
KR (1) | KR20060109816A (en) |
CN (1) | CN1822814A (en) |
AR (1) | AR045975A1 (en) |
AU (1) | AU2003286826A1 (en) |
BR (1) | BR0318373A (en) |
CA (1) | CA2530357A1 (en) |
IL (1) | IL172781A0 (en) |
MA (1) | MA27863A1 (en) |
MX (1) | MXPA05014193A (en) |
NO (1) | NO20060295L (en) |
PL (1) | PL379263A1 (en) |
RU (1) | RU2332985C2 (en) |
WO (1) | WO2005009408A2 (en) |
ZA (1) | ZA200600698B (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
NZ537953A (en) | 2002-07-31 | 2007-02-23 | Alza Corp | Injectable multimodal polymer depot compositions and uses thereof |
ATE418323T1 (en) * | 2002-11-06 | 2009-01-15 | Alza Corp | DEPOSIT DELAYED RELEASE FORMULATIONS |
SI1575569T1 (en) | 2002-12-13 | 2010-12-31 | Durect Corp | Oral drug delivery system comprising high viscosity liquid carrier materials |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
AU2004227985B2 (en) * | 2003-03-31 | 2009-04-02 | Intarcia Therapeutics, Inc. | Osmotic pump with means for dissipating internal pressure |
CL2004000697A1 (en) * | 2003-03-31 | 2005-05-20 | Alza Corp | OSMOTIC ADMINISTRATION DEVICE THAT INCLUDES: A RESERVE, AN OSMOTIC COMPOSITION, DRUG FORMULATION, AND A PRE-CHARGED MEMBRANE THAT INCLUDES A SEMIPERMEABLE MATERIAL AND A SELECTED POLYETHER LIQUID MATERIAL |
DE602004015755D1 (en) * | 2003-03-31 | 2008-09-25 | Alza Corp | NON-AQUEOUS SINGLE-PHASE VEGETABLE VEHICLES AND FORMULATIONS THAT USE THESE VEHICLES |
US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
US9114198B2 (en) * | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
BRPI0515372B8 (en) | 2004-09-17 | 2021-05-25 | Durect Corp | liquid composition to provide prolonged local anesthesia after administration to an individual, and use of bupivacaine, sucrose acetate isobutyrate and benzyl alcohol |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
KR101728868B1 (en) | 2006-01-18 | 2017-05-02 | 포시 파마슈티컬스 컴퍼니 리미티드 | Pharmaceutical compositions with enhanced stability |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
US7875697B2 (en) | 2006-06-29 | 2011-01-25 | Medtronic, Inc. | Poly(orthoester) polymers, and methods of making and using same |
ES2398126T3 (en) | 2006-08-09 | 2013-03-13 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
US8599926B2 (en) | 2006-10-12 | 2013-12-03 | Qualcomm Incorporated | Combined run-length coding of refinement and significant coefficients in scalable video coding enhancement layers |
EP1917971A1 (en) * | 2006-10-27 | 2008-05-07 | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) | Substained release formulations comprising very low molecular weight polymers |
PL2117521T3 (en) | 2006-11-03 | 2012-11-30 | Durect Corp | Transdermal delivery systems comprising bupivacaine |
MX2009011123A (en) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Suspension formulations of insulinotropic peptides and uses thereof. |
US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
EP2209450A4 (en) * | 2007-11-07 | 2013-09-25 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
AU2008347158B8 (en) * | 2007-12-06 | 2013-08-22 | Durect Corporation | Oral pharmaceutical dosage forms |
DK2240155T3 (en) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Devices, formulations and methods for the delivery of several beneficial agents |
US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
US8956642B2 (en) | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
US8940315B2 (en) | 2008-04-18 | 2015-01-27 | Medtronic, Inc. | Benzodiazepine formulation in a polyorthoester carrier |
US20090263456A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and Compositions for Reducing Preventing and Treating Adhesives |
PL2291174T3 (en) * | 2008-06-03 | 2015-06-30 | Tolmar Therapeutics Inc | Flowable composition comprising biocompatible oligomer-polymer compositions |
US20100016808A1 (en) * | 2008-07-17 | 2010-01-21 | Bioform Medical, Inc. | Thin-Walled Delivery System |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US20100203102A1 (en) * | 2009-02-10 | 2010-08-12 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using bupivacaine and an anti-onflammatory agent |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
NZ747990A (en) | 2009-09-28 | 2020-06-26 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
MX361709B (en) | 2009-11-09 | 2018-12-07 | Allergan Inc | Compositions and methods for stimulating hair growth. |
EP2552409A1 (en) * | 2010-04-01 | 2013-02-06 | Pharmanest AB | Bioadhesive compositions of local anaesthetics |
US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2717914B1 (en) | 2011-06-10 | 2019-10-30 | Ramscor, Inc. | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
CN103142458B (en) * | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | Without prescription and the preparation method of additive analgesia sustained release drug delivery systems |
WO2014127243A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
CN105120839B (en) | 2013-02-28 | 2020-07-28 | 湖州惠中济世生物科技有限公司 | Injectable long-acting local anesthetic semisolid preparation and composition components thereof |
US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
US9555113B2 (en) | 2013-03-15 | 2017-01-31 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
JP2017508004A (en) | 2014-02-18 | 2017-03-23 | エイブラムソーン, グレン | Compositions and methods for pain relief without paralysis |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
NZ738102A (en) | 2015-06-03 | 2024-02-23 | Intarcia Therapeutics Inc | Implant placement and removal systems |
AU2016352007B2 (en) | 2015-11-12 | 2022-03-17 | Terumo Kabushiki Kaisha | Sustained-release topically administered agent |
TWI814219B (en) | 2016-05-16 | 2023-09-01 | 美商因塔希亞治療公司 | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
IT201800001890A1 (en) * | 2018-01-25 | 2019-07-25 | Fidia Farm Spa | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POSTOPERATIVE PAIN |
KR20220140711A (en) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods |
Family Cites Families (340)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US557461A (en) * | 1896-03-31 | Andrew j | ||
US2931802A (en) | 1958-04-30 | 1960-04-05 | Eastman Kodak Co | Mixed esters of glucose and sucrose |
GB1088992A (en) | 1963-09-19 | 1967-10-25 | Squibb & Sons Inc | Protective dressings |
GB1218430A (en) * | 1967-11-07 | 1971-01-06 | Burton Parsons Chemicals Inc | Composition for treatment of pruritis ani |
US3412890A (en) | 1967-12-22 | 1968-11-26 | Clark Mfg Co J L | Hinged container closure |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US3743398A (en) | 1971-03-22 | 1973-07-03 | Eastman Kodak Co | Motion picture projector |
NO139560C (en) | 1972-04-29 | 1979-04-04 | Takeda Chemical Industries Ltd | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE NONAPEPTIDAMIDE DERIVATIVES |
US3797492A (en) * | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US3828389A (en) * | 1973-03-09 | 1974-08-13 | R Heisler | Unitary container having a hinged panel with a tray configuration |
SE7413710L (en) | 1973-11-01 | 1975-05-02 | Wellcome Found | |
US3923939A (en) | 1974-06-07 | 1975-12-02 | Alza Corp | Process for improving release kinetics of a monolithic drug delivery device |
DE2438352A1 (en) | 1974-08-09 | 1976-02-26 | Hoechst Ag | PEPTIDE CYCLOPROPYLAMIDE WITH LH-RH / FSHRH EFFECT |
DE2438350C3 (en) | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptides with a strong LH-RH / FSH-RH action, process for their production and pharmaceutical preparations containing them |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4131648A (en) | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4180646A (en) | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
JPS5194273A (en) | 1975-02-15 | 1976-08-18 | ||
US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
JPS55154991A (en) | 1979-05-23 | 1980-12-02 | Hisamitsu Pharmaceut Co Inc | Beta-d-fructopyranoside derivative |
NZ194405A (en) | 1979-08-02 | 1982-05-25 | Dut Pty Ltd | Producing liquid hydrocarbon streams by hydrogenation of fossil-based feedstock |
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4322323A (en) | 1980-12-01 | 1982-03-30 | Alza Corporation | Erodible device comprising surfactant for modifying the rate of erosion of the device |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
LU83485A1 (en) * | 1981-07-09 | 1983-02-04 | Metallurgie Hoboken | METHOD AND INSTALLATION FOR CASTING A SIDE PROJECTED EARBAND |
US4443340A (en) * | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
DE3716302C2 (en) | 1987-05-15 | 1996-02-01 | Henkel Kgaa | Improved absorbable bone waxes and their use |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
JPS59210024A (en) | 1983-05-13 | 1984-11-28 | Taiyo Kagaku Kk | Emulsified tocopherol |
US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4568559A (en) | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
US4708861A (en) | 1984-02-15 | 1987-11-24 | The Liposome Company, Inc. | Liposome-gel compositions |
US6217911B1 (en) * | 1995-05-22 | 2001-04-17 | The United States Of America As Represented By The Secretary Of The Army | sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
GB8416234D0 (en) | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
US4549010A (en) | 1984-06-27 | 1985-10-22 | Merck & Co., Inc. | Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal |
US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
JPS62419A (en) | 1985-06-26 | 1987-01-06 | Shiseido Co Ltd | Water-soluble agent containing fat-soluble vitamin |
US4780319A (en) | 1985-07-08 | 1988-10-25 | Merck & Co., Inc. | Organic acids as catalysts for the erosion of polymers |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US4780320A (en) | 1986-04-29 | 1988-10-25 | Pharmetrix Corp. | Controlled release drug delivery system for the periodontal pocket |
DE3750145T2 (en) | 1986-06-10 | 1994-11-03 | Euro Celtique Sa | Controlled release composition of dihydrocodeine. |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
IT1198449B (en) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
US5391381A (en) | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US4795641A (en) | 1987-08-20 | 1989-01-03 | Eastman Kodak Company | Polymer blends having reverse phase morphology for controlled delivery of bioactive agents |
US4866050A (en) * | 1988-04-27 | 1989-09-12 | Ben Amoz Daniel | Ultrasonic transdermal application of steroid compositions |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US4957998A (en) | 1988-08-22 | 1990-09-18 | Pharmaceutical Delivery Systems, Inc. | Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages |
US5181914A (en) * | 1988-08-22 | 1993-01-26 | Zook Gerald P | Medicating device for nails and adjacent tissue |
JPH0296516A (en) | 1988-09-29 | 1990-04-09 | Dainippon Pharmaceut Co Ltd | Granule and production thereof |
US5725491A (en) | 1988-10-03 | 1998-03-10 | Atrix Laboratories, Inc. | Method of forming a biodegradable film dressing on tissue |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5632727A (en) * | 1988-10-03 | 1997-05-27 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
US5085866A (en) * | 1988-12-02 | 1992-02-04 | Southern Research Institute | Method of producing zero-order controlled-released devices |
US5057318A (en) | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5059423A (en) | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US4946931A (en) | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
US5487897A (en) * | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
US5300295A (en) * | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
IT1240643B (en) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN |
US5110685A (en) | 1990-05-18 | 1992-05-05 | Exxon Chemical Patents, Inc. | Low friction, abrasion resistant polymer coating |
US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
NZ239370A (en) | 1990-08-22 | 1994-04-27 | Merck & Co Inc | Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
US5151093A (en) | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
US5620700A (en) * | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
AU8935591A (en) * | 1990-10-30 | 1992-05-26 | Alza Corporation | Drug delivery system and method |
US6117425A (en) | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
GB9027422D0 (en) * | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
WO1992011843A1 (en) | 1991-01-09 | 1992-07-23 | Alza Corporation | Bioerodible devices and compositions for diffusional release of agents |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU669479B2 (en) * | 1991-02-01 | 1996-06-13 | Massachusetts Institute Of Technology | Biodegradable polymer blends for delivery of biologically active agent |
JPH05508266A (en) | 1991-04-03 | 1993-11-18 | イーストマン・コダック・カンパニー | Highly durable mask for dry etching GaAs |
US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5211951A (en) | 1991-07-24 | 1993-05-18 | Merck & Co., Inc. | Process for the manufacture of bioerodible poly (orthoester)s and polyacetals |
JP3313124B2 (en) | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | SEAMLESS CAPSULES CONTAINING A HYDROPHILIC SUBSTANCE AND PROCESS FOR PRODUCING THE SAME |
US5487898A (en) | 1991-08-26 | 1996-01-30 | Abbott Laboratories | Compositions and method for the sublingual or buccal administration therapeutic agents |
CA2103163C (en) | 1991-08-26 | 1998-10-20 | Mou-Ying Fu Lu | Compositions and methods for the sublingual or buccal administration of therapeutic agents |
US5288214A (en) * | 1991-09-30 | 1994-02-22 | Toshio Fukuda | Micropump |
IL103275A0 (en) | 1991-10-01 | 1993-02-21 | Lilly Co Eli | Injectable extended release formulations and methods |
YU87892A (en) | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
JP3313113B2 (en) | 1991-10-21 | 2002-08-12 | ペプテック リミテッド | Biocompatible implants for controlling ovulation in mares |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
DK0542364T3 (en) * | 1991-11-13 | 1996-03-11 | Glaxo Canada | Controlled release device |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
WO1993010758A1 (en) | 1991-12-05 | 1993-06-10 | Pitman-Moore, Inc. | A carbohydrate glass matrix for the sustained release of a therapeutic agent |
WO1993011754A1 (en) | 1991-12-11 | 1993-06-24 | The Procter & Gamble Company | Cetylpyridinium chloride and domiphen bromide in organic solvent |
DE69230032T2 (en) * | 1991-12-19 | 2000-02-03 | Mitsui Chemicals Inc | POLYHYDROXYCARBOXYLIC ACID AND METHOD FOR THE PRODUCTION THEREOF |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5456679A (en) | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
EP0560014A1 (en) | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
WO1993019739A1 (en) * | 1992-03-30 | 1993-10-14 | Alza Corporation | Viscous suspensions of controlled-release drug particles |
MX9301821A (en) | 1992-03-30 | 1994-03-31 | Alza Corp | BIODEGRADABLE POLYMERICAL MATRIX SYSTEM DEGRADATION REGULATOR AND METHOD OF TREATMENT OF THE SAME. |
GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
US5618563A (en) * | 1992-09-10 | 1997-04-08 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
JPH08503950A (en) * | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | Microspheres containing sustained release growth hormone |
MY113268A (en) | 1992-12-29 | 2002-01-31 | Insite Vision Incorporated | Plasticized bioerodible controlled delivery system |
JPH08505138A (en) | 1992-12-29 | 1996-06-04 | インサイト・ビジョン・インコーポレイテッド | Biodegradable sustained release drug delivery system |
ATE236655T1 (en) | 1993-01-06 | 2003-04-15 | Kinerton Ltd | IONIC MOLECULAR CONJUGATES OF BIODEGRADABLE POLYESTERS AND BIOACTIVE POLYPEPTIDES |
US5340572A (en) | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
US5340614A (en) * | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
AU679511B2 (en) | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
JPH08507792A (en) | 1993-03-17 | 1996-08-20 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Aerosol formulations containing dispersion aids derived from diol-diacids |
DK44193D0 (en) | 1993-04-20 | 1993-04-20 | Euromed I S | SPECIAL CONNECTION AND ADMINISTRATIVE TO A SPECIAL CONNECTION OR SIMILAR |
US5330452A (en) * | 1993-06-01 | 1994-07-19 | Zook Gerald P | Topical medicating device |
US5447725A (en) | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
JP3189175B2 (en) | 1993-07-02 | 2001-07-16 | 出光興産株式会社 | Method for producing aromatic vinyl compound copolymer |
US5415866A (en) * | 1993-07-12 | 1995-05-16 | Zook; Gerald P. | Topical drug delivery system |
JP3257750B2 (en) | 1993-07-20 | 2002-02-18 | エチコン・インコーポレーテツド | Liquid copolymer of ε-caprolactone and lactide |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
JPH0753356A (en) | 1993-08-16 | 1995-02-28 | Morishita Jintan Kk | Seamless capsule containing easily oxidizable oily substance and its production |
TW282403B (en) | 1993-08-26 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
US5578137A (en) | 1993-08-31 | 1996-11-26 | E. I. Du Pont De Nemours And Company | Azeotropic or azeotrope-like compositions including 1,1,1,2,3,4,4,5,5,5-decafluoropentane |
WO1995009613A1 (en) | 1993-10-04 | 1995-04-13 | Mark Chasin | Controlled release microspheres |
US5849763A (en) * | 1993-10-13 | 1998-12-15 | Darwin Discovery Limited | Use of levobupivacaine as an anesthetic agent |
DK0727210T3 (en) * | 1993-10-13 | 2002-04-15 | Darwin Discovery Ltd | Analgesic agent and its use |
GB9321061D0 (en) | 1993-10-13 | 1993-12-01 | Chiroscience Ltd | Analgestic agent and its use |
US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
JPH07115901A (en) | 1993-10-28 | 1995-05-09 | Fuji Bibaretsuji:Kk | Emulsified composition and drink rich in docosahexaenoic acid |
EP0729351B1 (en) | 1993-11-16 | 2000-09-13 | SkyePharma Inc. | Vesicles with controlled release of actives |
EP2283821A1 (en) | 1993-11-19 | 2011-02-16 | Alkermes, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
WO1995017901A1 (en) | 1993-12-29 | 1995-07-06 | Matrix Pharmaceutical, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
CA2181048C (en) * | 1994-01-14 | 2003-05-06 | Lee Shahinian, Jr. | A method for sustained and extended corneal analgesia |
US5760077A (en) * | 1994-01-14 | 1998-06-02 | Shahinian, Jr.; Lee | Topical ophthalmic analgesic preparations for sustained and extended corneal analgesia |
US5556905A (en) | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
JPH09511666A (en) * | 1994-04-08 | 1997-11-25 | アトリックス・ラボラトリーズ・インコーポレイテッド | Ancillary polymer systems for use in medical devices |
BR9507313B8 (en) * | 1994-04-08 | 2016-06-07 | Atrix Lab Inc | liquid release composition suitable for the formation of a controlled release implant, polymeric system, biodegradable microporous film dressing, and precursor of a controlled release implant for implantation in an individual |
US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5599534A (en) * | 1994-08-09 | 1997-02-04 | University Of Nebraska | Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use |
US5786484A (en) | 1994-09-23 | 1998-07-28 | Chiroscience Limited | Racemization and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof |
US5599852A (en) | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
CA2200355C (en) | 1994-10-25 | 2007-03-06 | Marianne Langston | Crystallisation of levobupivacaine and analogues thereof |
DE69531624T2 (en) | 1994-10-25 | 2004-06-17 | Darwin Discovery Ltd., Slough | METHOD FOR PRODUCING LEVOBUPIVACAINE AND ANALOG |
US5660817A (en) * | 1994-11-09 | 1997-08-26 | Gillette Canada, Inc. | Desensitizing teeth with degradable particles |
US5607686A (en) | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US6333021B1 (en) * | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
WO1996021427A1 (en) | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
US6384227B2 (en) | 1995-01-18 | 2002-05-07 | Darwin Discovery Ltd. | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents |
GB9501071D0 (en) | 1995-01-18 | 1995-03-08 | Chiroscience Ltd | Racemisation |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
US5492253A (en) * | 1995-03-24 | 1996-02-20 | Proshan; Mary-Elizabeth | Cap attachment for small neck plastic bottle of liquid |
US5972326A (en) | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
US6322548B1 (en) | 1995-05-10 | 2001-11-27 | Eclipse Surgical Technologies | Delivery catheter system for heart chamber |
CA2222567C (en) | 1995-06-07 | 2002-01-29 | Southern Biosystems, Inc. | High viscosity liquid controlled biologically active delivery system |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5674292A (en) | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
CN1156961A (en) | 1995-06-09 | 1997-08-13 | 欧罗赛铁克股份有限公司 | Formulations and method for providing prolonged local anesthesia |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
US5787175A (en) * | 1995-10-23 | 1998-07-28 | Novell, Inc. | Method and apparatus for collaborative document control |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
PT877599E (en) | 1996-02-02 | 2003-08-29 | Alza Corp | CONTINUOUS LEUPROLIDAL ADMINISTRATION USING AN IMPLANTABLE SYSTEM |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
IT1283252B1 (en) | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | SOLUTIONS OF PIROXICAM INJECTABLE BY PARENTERAL WAY |
US5747060A (en) * | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
CN1126537C (en) * | 1996-05-23 | 2003-11-05 | 株式会社三养社 | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
EP0954301A4 (en) | 1996-06-24 | 2006-03-08 | Euro Celtique Sa | Methods for providing safe local anesthesia |
CA2180601C (en) * | 1996-07-05 | 2007-12-18 | Chun Keung Mak | Heated nozzle manifolds in a common plane interconnected through connector manifolds |
BR9710289A (en) * | 1996-07-11 | 1999-08-17 | Farmarc Nederland Bv | Pharmaceutical composition containing acid salt with basic medicine addition |
US5869669A (en) | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
AU4249597A (en) * | 1996-09-04 | 1998-03-26 | Ht Medical Systems, Inc. | Interventional radiology interface apparatus and method |
US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
US5747051A (en) | 1996-09-27 | 1998-05-05 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid |
US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
EP0959873B1 (en) | 1996-12-20 | 2006-03-01 | ALZA Corporation | Gel composition and methods |
US6203813B1 (en) | 1997-01-13 | 2001-03-20 | Lance L. Gooberman | Pharmaceutical delivery device and method of preparation therefor |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
GB9704351D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
DE19714765A1 (en) | 1997-04-10 | 1998-10-15 | Merck Patent Gmbh | Use of low molecular weight, oligomeric esters of alpha-hydroxy acids and / or aromatic o-hydroxy acids in cosmetic formulations |
US5919473A (en) | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6004295A (en) | 1997-06-26 | 1999-12-21 | An-Go-Gen Inc. | Catheters |
AU739384B2 (en) * | 1997-07-02 | 2001-10-11 | Euro-Celtique S.A. | Prolonged anesthesia in joints and body spaces |
US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US20010004644A1 (en) * | 1997-07-21 | 2001-06-21 | Levin Bruce H. | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
DE69814394T2 (en) * | 1997-07-22 | 2004-03-11 | Darwin Discovery Ltd., Slough | USE OF LEVOBUPIVACAIN |
CA2296080C (en) | 1997-07-29 | 2005-02-01 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
ATE535232T1 (en) | 1997-09-18 | 2011-12-15 | Pacira Pharmaceuticals Inc | SUSTAINED RELEASE OF LIPOSOMAL ANESTHETICAL COMPOSITIONS |
US6183444B1 (en) | 1998-05-16 | 2001-02-06 | Microheart, Inc. | Drug delivery module |
US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
AU752802C (en) | 1997-11-14 | 2006-04-13 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
CA2308495C (en) | 1997-11-19 | 2009-01-06 | Darwin Discovery Limited | Anaesthetic formulation |
AU737661B2 (en) | 1997-11-27 | 2001-08-23 | Nihon Seikan Kabushiki Kaisha | Metallic can and method of manufacture of same, and can cover with integral scraper |
US6050986A (en) * | 1997-12-01 | 2000-04-18 | Scimed Life Systems, Inc. | Catheter system for the delivery of a low volume liquid bolus |
IT1298574B1 (en) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF POLYMER-BASED MICROPARTICLES OBTAINED BY EXTRUSION AND SPHERONIZATION |
AU745841B2 (en) | 1998-03-19 | 2002-04-11 | Merck Sharp & Dohme Corp. | Liquid polymeric compositions for controlled release of bioactive substances |
WO1999049908A1 (en) * | 1998-03-31 | 1999-10-07 | University Of Cincinnati | Temperature controlled solute delivery system |
US6261547B1 (en) * | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US7128927B1 (en) | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
GB9808720D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
US5939453A (en) | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
CA2335837A1 (en) | 1998-06-29 | 2000-01-06 | Pharmaceuticals Applications Associates, Llc | Methods and transdermal compositions for pain relief |
US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6605294B2 (en) | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US7662409B2 (en) * | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6955819B2 (en) | 1998-09-29 | 2005-10-18 | Zars, Inc. | Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6102235A (en) | 1998-12-18 | 2000-08-15 | Stern; Max M. | Lid with integral paint roller tray |
DE19858891A1 (en) | 1998-12-19 | 2000-06-21 | Merck Patent Gmbh | Improved bone seals |
US6451346B1 (en) | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US6498153B1 (en) | 1998-12-31 | 2002-12-24 | Akzo Nobel N.V. | Extended release growth promoting two component composition |
US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
RU2271196C2 (en) | 1999-06-04 | 2006-03-10 | Элзэ Копэрейшн | Implantable composition (variants) and method for production thereof |
WO2000078335A1 (en) | 1999-06-18 | 2000-12-28 | Southern Biosystems, Inc. | COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS |
DE19932157A1 (en) | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Process for the gentle production of ultra-fine microparticles and nanoparticles |
US6423818B1 (en) * | 1999-07-30 | 2002-07-23 | Takehisa Matsuda | Coumarin endcapped absorbable polymers |
US6352667B1 (en) * | 1999-08-24 | 2002-03-05 | Absorbable Polymer Technologies, Inc. | Method of making biodegradable polymeric implants |
US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
US6566345B2 (en) * | 2000-04-28 | 2003-05-20 | Fziomed, Inc. | Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
WO2001049338A1 (en) * | 1999-12-30 | 2001-07-12 | Li Wei Pin | Controlled delivery of therapeutic agents by insertable medical devices |
EP1248596B1 (en) | 2000-01-11 | 2007-03-07 | Roland Bodmeier | Implantation kit comprising a support phase and a solvent |
FR2804066B1 (en) | 2000-01-25 | 2002-05-31 | Franpin | PAINT BIN WITH ROLL HOLDING MEANS |
US6447604B1 (en) | 2000-03-13 | 2002-09-10 | Advanced Technology Materials, Inc. | Method for achieving improved epitaxy quality (surface texture and defect density) on free-standing (aluminum, indium, gallium) nitride ((al,in,ga)n) substrates for opto-electronic and electronic devices |
BR0002246A (en) | 2000-04-06 | 2003-04-15 | Cristalia Prod Quimicos Farm | Process for obtaining the enantiomers of racemic bupivacaine, process for obtaining pharmaceutical compositions based on levobupivacaine: pharmaceutical compositions based on levobupivacaine formulated in basic forms or pharmaceutically acceptable salts and use of pharmaceutical compositions based on levobupivacaine formulated in basic forms or pharmaceutically salts acceptable |
ATE309822T1 (en) | 2000-04-19 | 2005-12-15 | Genentech Inc | SUSTAINED RELEASE FORMULATIONS CONTAINING GROWTH HORMONE |
AU2001255716B2 (en) * | 2000-04-28 | 2006-02-02 | Fziomed, Inc. | Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use |
US6613355B2 (en) * | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
US20050042194A1 (en) | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
DE60115631T2 (en) | 2000-05-11 | 2006-08-10 | AP Pharma, Inc., Redwood | HALF-SENSITIVE ADMINISTRATIVE MEDICINAL PRODUCTS |
CA2413157A1 (en) | 2000-06-28 | 2002-01-03 | Atul J. Shukla | Biodegradable vehicles and delivery systems of biologically active substances |
AU2001273099A1 (en) | 2000-07-13 | 2002-01-30 | Guilford Pharmaceuticals Inc. | Substituted 4,9-dihydrocyclopenta(imn) phenanthridine-5-ones, derivatives thereof and their uses |
WO2002005800A2 (en) * | 2000-07-17 | 2002-01-24 | Guilford Pharmaceuticals, Inc. | Compositions for sustained release of analgesic agents, and methods of making and using the same |
WO2002010436A2 (en) | 2000-07-28 | 2002-02-07 | The Brigham And Women's Hospital, Inc. | Prognostic classification of breast cancer |
US6362308B1 (en) * | 2000-08-10 | 2002-03-26 | Alkermes Controlled Therapeutics Inc. Ii | Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content |
US6543081B1 (en) * | 2000-08-15 | 2003-04-08 | Sheldon C. Cohen | Flip-up wringer sponge mop |
DE10044545A1 (en) | 2000-09-05 | 2002-04-04 | Roland Bodmeier | Retardpartikeldispersion |
FR2814308B1 (en) | 2000-09-15 | 2003-03-14 | France Telecom | METHOD FOR MANAGING THE USE OF A TELECOMMUNICATION LINE AND SYSTEM FOR IMPLEMENTING IT |
US6823084B2 (en) * | 2000-09-22 | 2004-11-23 | Sri International | Method and apparatus for portably recognizing text in an image sequence of scene imagery |
MXPA03003895A (en) | 2000-10-30 | 2003-07-28 | Euro Celtique Sa | Controlled release hydrocodone formulations. |
AU2002226000A1 (en) | 2000-11-13 | 2002-05-21 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
US20020141966A1 (en) | 2000-11-16 | 2002-10-03 | Wenbin Dang | Compositions for treatment of malignant effusions, and methods of making and using the same |
KR100446101B1 (en) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | Sustained delivery composition for poorly water soluble drugs |
JP2004521111A (en) | 2001-01-25 | 2004-07-15 | ユーロ−セルティーク,エス.エイ. | Local anesthetics and usage |
US6375659B1 (en) * | 2001-02-20 | 2002-04-23 | Vita Licensing, Inc. | Method for delivery of biocompatible material |
JP4724354B2 (en) | 2001-02-23 | 2011-07-13 | ジェネンテック, インコーポレイテッド | Disintegrating polymer for injection |
US20040018238A1 (en) | 2001-02-26 | 2004-01-29 | Shukla Atul J | Biodegradable vehicles and delivery systems of biolgically active substances |
US20020148846A1 (en) | 2001-04-12 | 2002-10-17 | Ropak Corporation | Container lid having gasketless liquid seal |
US6590059B2 (en) | 2001-05-11 | 2003-07-08 | Ap Pharma, Inc. | Bioerodible polyorthoesters from dioxolane-based diketene acetals |
US20020176844A1 (en) | 2001-05-11 | 2002-11-28 | Ng Steven Y. | Bioerodible polyorthoesters containing hydrogen bonding groups |
US20030152630A1 (en) | 2001-05-11 | 2003-08-14 | Ng Steven Y. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
ES2554106T3 (en) | 2001-06-21 | 2015-12-16 | Genentech, Inc. | Sustained Release Formulation |
ES2329346T3 (en) * | 2001-11-14 | 2009-11-25 | Durect Corporation | COMPOSITION OF INJECTABLE DEPOSIT. |
IL162001A0 (en) | 2001-11-14 | 2005-11-20 | Alza Corp | Catheter injectable depot compositions and uses thereof |
BR0206984A (en) | 2001-11-14 | 2004-02-03 | Alza Corp | Injectable Depot Compositions and Use of These |
US6524606B1 (en) | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
US6833139B1 (en) | 2002-01-09 | 2004-12-21 | Ferndale Laboratories, Inc. | Composition and method for the treatment of anorectal disorders |
US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
FR2838349B1 (en) | 2002-04-15 | 2004-06-25 | Laurence Paris | LIQUID COMPOSITIONS FOR SUSTAINED RELEASE SOFT CAPSULES AND PROCESS FOR PRODUCING THE SAME |
ES2665999T3 (en) | 2002-05-31 | 2018-04-30 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
AR039729A1 (en) | 2002-06-25 | 2005-03-09 | Alza Corp | SHORT-TERM DEPOSIT FORMULATIONS |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US20040109893A1 (en) | 2002-06-25 | 2004-06-10 | Guohua Chen | Sustained release dosage forms of anesthetics for pain management |
JP4417039B2 (en) | 2002-06-28 | 2010-02-17 | 太陽化学株式会社 | Oil-in-water emulsion composition |
JP4712380B2 (en) | 2002-07-26 | 2011-06-29 | 三笠製薬株式会社 | Topical preparation |
US8252303B2 (en) | 2002-07-31 | 2012-08-28 | Durect Corporation | Injectable depot compositions and uses thereof |
NZ537953A (en) | 2002-07-31 | 2007-02-23 | Alza Corp | Injectable multimodal polymer depot compositions and uses thereof |
US7070582B2 (en) | 2002-08-09 | 2006-07-04 | Boston Scientific Scimed, Inc. | Injection devices that provide reduced outflow of therapeutic agents and methods of delivering therapeutic agents |
RU2310450C2 (en) | 2002-10-25 | 2007-11-20 | Пфайзер Продактс Инк. | Novel depot-preparations for injection |
JP2006505579A (en) | 2002-10-25 | 2006-02-16 | ファイザー・プロダクツ・インク | Accumulated formulations of aryl heterocyclic active drugs in suspension form |
US20040151774A1 (en) | 2002-10-31 | 2004-08-05 | Pauletti Giovanni M. | Therapeutic compositions for drug delivery to and through covering epithelia |
ATE418323T1 (en) | 2002-11-06 | 2009-01-15 | Alza Corp | DEPOSIT DELAYED RELEASE FORMULATIONS |
US7045589B2 (en) | 2002-11-15 | 2006-05-16 | A.P. Pharma, Inc. | Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
US6863782B2 (en) | 2002-11-15 | 2005-03-08 | A.P. Pharma, Inc. | Method of preparing di(ketene acetals) |
US7491234B2 (en) | 2002-12-03 | 2009-02-17 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents |
SI1575569T1 (en) | 2002-12-13 | 2010-12-31 | Durect Corp | Oral drug delivery system comprising high viscosity liquid carrier materials |
KR20050088196A (en) | 2002-12-19 | 2005-09-02 | 알자 코포레이션 | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
DK2526996T3 (en) | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulation for intracutaneous injection |
CA2518791A1 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell-schedule dependent anticancer agents |
DE10312346A1 (en) | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Controlled release system |
DE10322469A1 (en) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclic compounds |
EP1643968A1 (en) | 2003-05-30 | 2006-04-12 | ALZA Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
US20050106304A1 (en) | 2003-11-14 | 2005-05-19 | Cook Phillip M. | Sucrose acetate isobutyrate formulation |
US20050171052A1 (en) | 2003-11-14 | 2005-08-04 | Cook Phillip M. | Sucrose acetate isobutyrate formulation |
US20050232876A1 (en) | 2004-04-19 | 2005-10-20 | Robin Lynn Minga | Skin care compositions |
EP1758095A4 (en) | 2004-05-14 | 2008-10-01 | Yanmar Co Ltd | Noise suppressing structure of cabin |
US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
US7269958B2 (en) | 2004-09-10 | 2007-09-18 | Pratt & Whitney Canada Corp. | Combustor exit duct |
BRPI0515372B8 (en) | 2004-09-17 | 2021-05-25 | Durect Corp | liquid composition to provide prolonged local anesthesia after administration to an individual, and use of bupivacaine, sucrose acetate isobutyrate and benzyl alcohol |
US20060263433A1 (en) | 2005-02-03 | 2006-11-23 | Ayer Rupal A | Suspension formulation of interferon |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
JP5194273B2 (en) | 2007-09-20 | 2013-05-08 | 三菱電機株式会社 | Semiconductor device |
SE531980C2 (en) | 2008-01-17 | 2009-09-22 | Avtech Sweden Ab | Flight control procedure as well as computer programs and computer program product to carry out the procedure |
US8980317B2 (en) | 2008-12-23 | 2015-03-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating infections comprising a local anesthetic |
-
2003
- 2003-06-25 US US10/606,969 patent/US20040001889A1/en not_active Abandoned
- 2003-10-31 AU AU2003286826A patent/AU2003286826A1/en not_active Abandoned
- 2003-10-31 RU RU2006101985/15A patent/RU2332985C2/en not_active IP Right Cessation
- 2003-10-31 BR BRPI0318373-4A patent/BR0318373A/en not_active IP Right Cessation
- 2003-10-31 EP EP03778041A patent/EP1638519A2/en not_active Withdrawn
- 2003-10-31 CA CA002530357A patent/CA2530357A1/en not_active Abandoned
- 2003-10-31 WO PCT/US2003/034763 patent/WO2005009408A2/en active Application Filing
- 2003-10-31 CN CNA2003801103931A patent/CN1822814A/en active Pending
- 2003-10-31 PL PL379263A patent/PL379263A1/en not_active Application Discontinuation
- 2003-10-31 MX MXPA05014193A patent/MXPA05014193A/en unknown
- 2003-10-31 EP EP09001701A patent/EP2067468A1/en not_active Withdrawn
- 2003-10-31 JP JP2005504650A patent/JP2007521225A/en active Pending
- 2003-10-31 KR KR1020057024815A patent/KR20060109816A/en not_active Application Discontinuation
- 2003-12-10 AR ARP030104542A patent/AR045975A1/en not_active Application Discontinuation
-
2005
- 2005-12-22 IL IL172781A patent/IL172781A0/en unknown
- 2005-12-23 MA MA28682A patent/MA27863A1/en unknown
-
2006
- 2006-01-20 NO NO20060295A patent/NO20060295L/en not_active Application Discontinuation
- 2006-01-24 ZA ZA200600698A patent/ZA200600698B/en unknown
- 2006-04-03 US US11/278,472 patent/US20060165800A1/en not_active Abandoned
-
2010
- 2010-09-27 US US12/924,441 patent/US8278330B2/en not_active Expired - Fee Related
-
2016
- 2016-09-15 US US15/267,070 patent/US10201496B2/en not_active Expired - Lifetime
-
2018
- 2018-12-28 US US16/235,889 patent/US10471001B2/en not_active Expired - Fee Related
-
2019
- 2019-03-08 US US16/297,509 patent/US10471002B2/en not_active Expired - Fee Related
- 2019-09-26 US US16/584,698 patent/US11179326B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005009408B1 (en) | Sustained release dosage forms of anesthetics for pain management | |
RU2006101985A (en) | DOSED FORMES OF ANESTHESIC PRODUCTS WITH LONG-TERM RELEASE FOR ANALGESIS | |
US20040109893A1 (en) | Sustained release dosage forms of anesthetics for pain management | |
RU2005117164A (en) | CONTINUED ACTION COMPOSITIONS WITH CONTROLLED RELEASE | |
EP2394663B1 (en) | Compositions for injectable in-situ biodegradable implants | |
JP2006508127A5 (en) | ||
US5736152A (en) | Non-polymeric sustained release delivery system | |
EP2575890B1 (en) | Antipsychotic injectable depot composition | |
US10592168B1 (en) | Injectable flowable composition comprising buprenorphine | |
CA2275525A1 (en) | Gel composition and methods | |
MX2012014335A (en) | Injectable flowable composition comprising buprenorphine. | |
JP2017513871A5 (en) | ||
CA2714757A1 (en) | Low viscosity liquid polymeric delivery system | |
EP1795185A2 (en) | Nano- and/or micro-particulate formulations for local injection-based treatment of vascular diseases | |
WO2009129439A4 (en) | Medical devices and methods including polymers having biologically active agents therein | |
WO2002038185A2 (en) | Injectable sustained release delivery system with loperamide | |
EP2983663B1 (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
Patel et al. | A review on PLGA based solvent induced in-situ forming implant | |
Namvar et al. | Effects of solvent type on in vitro lidocaineHCl release from PLGA-based in situ forming systems | |
OA16256A (en) | Antipsychotic injectable depot composition. | |
NZ712804B2 (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |